Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

228,511-228,540 of 319,975

filter-aware
17
Includes detailed patient enrollment table by dose cohort and trial objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
19
Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
20
The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Swimmer plot showing patient-level treatment duration with ongoing status and response markers.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Includes two patient case studies with MRI scans showing baseline vs follow-up results.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Includes a detailed table of patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide uses a timeline-based framework to contrast treatment options with clinical limitations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
Data presented in two tables: Patient Characteristics and Treatment History.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
Includes a summary table of ORR and a waterfall plot of tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
Data as of 13 Sep 2022. Includes list of specific adverse events by grade.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
40
The slide uses three distinct chart types to demonstrate the drug's efficacy and safety profile.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
41
The slide uses a timeline framework to connect current clinical program statuses to a future milestone.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
42
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Slide 1
Includes company logo and date.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
02
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
03
The slide uses a circular crop for the image, which is a common design element in corporate presentations to soften the visual impact.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
04
The slide uses a circular photo of two professionals working together to humanize the corporate mission statement.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit